Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

NCT03850509 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Crohn's Disease

Interventions

DRUG: OPS-2071
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]